Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAN, Academy, amyloid, apprised, Austin, Ave, battery, behavioral, beta, betaxolol, Biomedical, biopharmaceutical, breaking, categorization, CEO, Clementi, coagulation, context, cybersecurity, dampen, disproportionate, emotional, everyday, Fellowship, filer, float, forecast, forthcoming, FY, Germany, hallmarked, immaterial, imperative, interdisciplinary, ISNI, Izzy, Jumpstart, Lorex, Ludden, McNay, mental, Milan, moa, multitude, Munich, Neurocritical, Neuroimmunology, neuroinflammation, neuroinflammatory, NeuroQoL, NIH, nitiated, ophthalmology, overseen, overwhelming, parameter, path, penetration, pgrogam, playbook, podium, posture, Quebec, ransomware, refined, relaxation, rodent, RPh, Saef, San, sector, sex, smooth, Society, stimulatory, subcontractor, symptom, Synthelabo, temperature, Tizana, TK, Topline, Tx, uncharacterized, uncommon, unfavorable, unrealized, vascular, William, zolpidem
Removed:
accelerating, amortised, Baroda, Bombay, capitalised, conditioned, consummation, dolcanatide, EGC, enteric, Floor, fringe, golden, intrinsic, licence, Maharaja, maximise, metabolic, microbiology, minimise, minimising, multinational, nonbinding, optimisation, Palejwala, parachute, participated, Plaza, plecanatide, profiling, receivable, recognised, recognising, Sanofi, Sayajirao, science, separation, SharDNA, SPA, spouse, stay, stemprinter, summarised, Trulance, unrealised, Vaseem
Filing tables
Filing exhibits
TLSA similar filings
Filing view
External links
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors of Tiziana Life Sciences Ltd:
We hereby consent to the incorporation by reference in Registration Statement on Form F-3 (File No. 333-252441) of our report dated May 20, 2022 with respect to the consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the year ended December 31, 2021, and the related notes, for Tiziana Life Sciences Ltd and its subsidiaries (the Group), which report appears in the December 31, 2023 Annual Report on Form 20-F to be filed on or about May 10, 2024.
/s/ Mazars LLP
Mazars LLP
London, United Kingdom
May 10, 2024